Array BioPharma Inc. (NASDAQ:ARRY)’s share price traded down 3.9% during trading on Wednesday . The company traded as low as $3.40 and last traded at $3.46, with a volume of 1,124,671 shares. The stock had previously closed at $3.60.

A number of equities analysts have commented on the company. Cantor Fitzgerald restated a “buy” rating on shares of Array BioPharma in a research note on Wednesday, May 4th. Leerink Swann reiterated a “buy” rating and issued a $6.00 price target on shares of Array BioPharma in a research note on Thursday, May 5th. Jefferies Group reiterated a “buy” rating on shares of Array BioPharma in a research note on Wednesday, May 4th. Zacks Investment Research upgraded Array BioPharma from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Tuesday, July 5th. Finally, SunTrust Banks Inc. started coverage on Array BioPharma in a research note on Thursday, June 2nd. They issued a “buy” rating and a $7.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $7.43.

The stock’s market cap is $497.43 million. The firm’s 50 day moving average is $3.68 and its 200-day moving average is $3.28.

Array BioPharma (NASDAQ:ARRY) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.02. The company earned $43.20 million during the quarter, compared to analyst estimates of $41.51 million. During the same quarter last year, the firm posted ($0.09) EPS. The company’s revenue was up 251.2% compared to the same quarter last year. On average, analysts forecast that Array BioPharma Inc. will post ($0.68) earnings per share for the current year.

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.